Drug Discovery & Pharmaceuticals

RSS

New AI framework enables reliable intracellular antibody design

A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable rapid conversion of antibody sequences into functional intracellular antibodies (intrabodies) that are stable within living cells.

13 Feb 2026

Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies

Tahoe Therapeutics - a biotech start-up based in San Francisco, California - is creating the largest ever atlas of cell-chemical interactions to inform drug discovery. Combining automated pipetting systems from INTEGRA Biosciences, Parse Biosciences' Evercode™ single-cell RNA sequencing (scRNA-seq) products, and its own proprietary AI algorithms, the company already has several drug discovery programs running in parallel across multiple cancer types, and is expanding into other therapeutic areas.

12 Feb 2026

SPT Labtech and Bellbrook Labs introduce high-throughput screening platform for cancer research

SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life sciences, and BellBrook Labs, a pioneer in high-throughput screening (HTS) assay tools, today announced a collaboration to advance cancer research.

9 Feb 2026

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug discovery, development, testing, and manufacturing solutions provider.

9 Feb 2026

AI model accelerates antibody production and clone selection

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

9 Feb 2026

Tumor-targeted chimeric drug increases efficacy and limits side effects

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively.

7 Feb 2026

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows.

5 Feb 2026

New platform improves prediction of human antibody drug responses

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The

1 Feb 2026

Evosep launches IQ/OQ protocols for the Evosep Eno System at WCBP 2026

Evosep is proud to announce a major advancement in quality assurance for pharmaceutical and regulated laboratories with the introduction of Installation Qualification (IQ) and Operational Qualification (OQ) protocols for its Evosep Eno system.

From Evosep 30 Jan 2026

CDD European Life Science Community Meeting

Collaborative Drug Discovery's Community Meeting brings the European technology and scientific communities together.

From CDD Vault 30 Jan 2026

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud Biosciences, an innovator in organoid development and complex 3D biology, today announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.

27 Jan 2026

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

27 Jan 2026

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

From WuXi Biologics 27 Jan 2026

Proimmune introduces Mastering Immunity 2026 - Shanghai symposium to address key immunogenicity challenges

ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 - Shanghai, an inaugural symposium in China providing practical, real-world guidance to help drug developers manage immunogenicity risk.

21 Jan 2026

Accelerating kinase drug discovery with validated kinase activity assay kits

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

From Eurofins Discovery 20 Jan 2026

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners.

From Concept Life Sciences 19 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Axol Bioscience raises $2.8 M to advance US expansion and product development

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding.

13 Jan 2026

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

12 Jan 2026

FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced the expansion of its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the Company's advanced laboratories in San Diego, CA.

12 Jan 2026

Drug Discovery & Pharmaceuticals

New AI framework enables reliable intracellular antibody design

Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies

SPT Labtech and Bellbrook Labs introduce high-throughput screening platform for cancer research

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

AI model accelerates antibody production and clone selection

Tumor-targeted chimeric drug increases efficacy and limits side effects

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

New platform improves prediction of human antibody drug responses

Evosep launches IQ/OQ protocols for the Evosep Eno System at WCBP 2026

CDD European Life Science Community Meeting

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

Proimmune introduces Mastering Immunity 2026 - Shanghai symposium to address key immunogenicity challenges

Accelerating kinase drug discovery with validated kinase activity assay kits

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

New chemistry revives neurokinin-1 receptor as depression treatment target

Axol Bioscience raises $2.8 M to advance US expansion and product development

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest Life Science News